Harder Endpoints Needed In Studies Of Hepatic Encephalopathy Drugs Like Salix's Xifaxan, Advisory Committee Says
Executive Summary
Future clinical trials of drugs for hepatic encephalopathy should be encouraged to seek hard endpoints, FDA's Gastrointestinal Drugs Advisory Committee suggested during its Feb. 23 review of Salix's Xifaxan (rifaximin)